|COA||Certificate of Analysis-Tasimelteon 609799-22-6 B16TSMT0425|
|Description||Tasimelteon (trade name Hetlioz) is a drug approved by the FDA solely for the treatment of non-24-hour sleep–wake disorder (often designated as N24HSWD) in totally blind adults. It is a selective agonist for the melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, similar to other members of the melatonin receptor agonist class of which ramelteon (2005) and agomelatine (2009) were the first approved.|
|B0084-072984||100 mg||$498||In stock|
|B0084-072984||1 g||$899||In stock|
|Brife Description||Tasimelteon is a novel circadian regulator, is the first product for the treatment of Non-24-hour Sleep-Wake Disorder (Non-24) approved by either the FDA or the European Medicines Agency (EMA).It is also a melatonin MT1 and MT2 receptor agonist.|
|Appearance||White to off-white Solid|
|Synonyms||BMS-214,778; BMS-214778; BMS214778; BMS 214778. VEC-162; VEC162; VEC 162. Trade name: Hetlioz.|
|Application||Tasimelteon is a novel drug, used in the treatment of non-24 hour sleep-wake disorder. It helps to correct the circadian rhythm disorder often seen in patients who are visually impaired.|
|Quality Standard||In-house Standard|
|Boiling Point||442.6±24.0 °C | Condition: Press: 760 Torr|
|Melting Point||57 - 65°C|
Ramelteon has high affinity with recombinant human MT1 and MT2 receptors with pKi of 10.05 and 9.70, respectively.
DH 97 is a selective MEL-1B-R (melatonin receptor) antagonist.
DH 97 is a potent MT2 melatonin receptor antagonist (pKi = 8.03) with 89- and 229-fold selectivity over MT1 and GPR50 (melatonin-related orphan receptor) respec...
2-Iodomelatonin is a potent agonist of the melatonin receptors 1 (MT1) with Ki value of 28 pM. It could be used to identify, characterize and localize melatonin...
Tasimelteon (trade name Hetlioz) is a drug approved by the FDA solely for the treatment of non-24-hour sleep–wake disorder (often designated as N24HSWD) in tota...
This active molecular is high affinity nonselective melatonin receptors MT1 and MT2 agonist which is under development for the treatment of insomnia and other s...
Luzindole is a melatonin receptor antagonist which preferentially targets MT1B.
6-Chloromelatonin is a potent agonist of the melatonin receptors, which is active at nanomolar concentrations. It shows higher affinity for binding to hamster b...